Current Study
CALM-2 | BUS-P3-02
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)
Study Status
Closed
Duration
Up to 71 weeks
Clinic Visits
Up to 20
Phone Check-ins
Up to 2
Study Overview
Location
TrialsWest Spearwood
Phase
Phase 3
Study Duration
Up to 71 weeks
Main Entry Criteria
- 18 – 80 years of age
- Persistent cough for 1 year or more prior to Screening
- Have had investigations to rule out potential underlying causes of cough
- Non-smoker
There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.
Main Exclusion Criteria
Assessments
- Blood pressure and pulse measurements
- Electronic Diary Questionnaires
- ECGs
- 24-hour cough monitor
- Blood and urine tests
At a Glance
Clinic Visits
Up to 20
Phone Calls
Up to 2
Duration
Up to 71 weeks